topic

IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells
Ksenia Magidey-Klein, Tim J Cooper, Ksenya Kveler, Rachelly Normand, Tongwu Zhang, Michael Timaner, Ziv Raviv, Brian P. James, Roi Gazit, Ze'ev A. Ronai, Shai Shen-Orr, Yuval Shaked

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002856; DOI: 10.1136/jitc-2021-002856
Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer
Tianhang Zhai, Chao Wang, Yifeng Xu, Weifeng Huang, Zhijun Yuan, Tao Wang, Shuang Dai, Shaogang Peng, Tuling Pang, Wenchao Jiang, Yuhua Huang, Yuefeng Zou, Yingda Xu, Joanne Sun, Xinjiang Gong, Jinping Zhang, Andy Tsun, Bin Li, Xiaoniu Miao

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002131; DOI: 10.1136/jitc-2020-002131
Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients
Alexandre Gérard, Jerome Doyen, Marion Cremoni, Laurent Bailly, Kevin Zorzi, Caroline Ruetsch-Chelli, Vesna Brglez, Alexandra Picard-Gauci, Laura Troin, Vincent L.M. Esnault, Thierry Passeron, Henri Montaudié, Barbara Seitz-Polski

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002512; DOI: 10.1136/jitc-2021-002512
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Jason D Goldman, Philip C Robinson, Thomas S Uldrick, Per Ljungman

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002630; DOI: 10.1136/jitc-2021-002630
Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell
Xing Huang, Gang Zhang, Tingbo Liang

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002823; DOI: 10.1136/jitc-2021-002823
Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling
Namita Varudkar, Jeremiah L Oyer, Alicja Copik, Griffith D Parks

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002373; DOI: 10.1136/jitc-2021-002373
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Yoland Antill, Peey-Sei Kok, Kristy Robledo, Sonia Yip, Michelle Cummins, Deborah Smith, Amanda Spurdle, Elizabeth Barnes, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, John Andrews, Martin R Stockler, Linda Mileshkin

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002255; DOI: 10.1136/jitc-2020-002255
Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients
Emanuela Romano, Steve Pascolo, Patrick Ott

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002932; DOI: 10.1136/jitc-2021-002932
S100A4 enhances protumor macrophage polarization by control of PPAR-γ-dependent induction of fatty acid oxidation
Shuangqing Liu, Huilei Zhang, Yanan Li, Yana Zhang, Yangyang Bian, Yanqiong Zeng, Xiaohan Yao, Jiajia Wan, Xu Chen, Jianru Li, Zhaoqing Wang, Zhihai Qin

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002548; DOI: 10.1136/jitc-2021-002548
Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
Alexander A Pieper, Alexander L Rakhmilevich, Daniel V Spiegelman, Ravi B Patel, Jen Birstler, Won Jong Jin, Peter M Carlson, Deborah H Charych, Jacquelyn A Hank, Amy K Erbe, Willem W Overwijk, Zachary S Morris, Paul M Sondel

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002715; DOI: 10.1136/jitc-2021-002715

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages